Scipher, Galapagos partner to develop IBD treatments

By The Science Advisory Board staff writers

August 14, 2020 -- Small molecule medicine company Galapagos and autoimmune precision medicine firm Scipher Medicine have announced a collaborative agreement to advance novel drug targets for inflammatory bowel disease (IBD).

The two companies will jointly validate multiple IBD targets discovered by Scipher. The partnership will leverage the precision medicine firm's proprietary, artificial intelligence (AI)-driven Network Medicine Platform and molecular patient data.

Under the terms of the agreement, Galapagos has the exclusive option to choose up to five candidates to progress further for drug discovery and development. Galapagos will also maintain rights for the discovery, development, and commercialization of therapeutics for developed targets, while Scripher is eligible to receive upfront, opt-in, and milestone payments.

Prometheus to develop antibody for IBD
Prometheus Biosciences has entered into an agreement with Dr. Falk Pharma for the development and commercialization of Pr600, a novel precision antibody,...
New research helps scientists understand the genetic cause of immune disease
Research published in Nature Genetics on September 23 helps narrow down the search for molecular drivers for immune disease which could result...

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
ESMO Virtual Congress 2020
September 14-29
2020 ACCP Annual Meeting
September 20-22
BioProcess International West
September 21-25
BioProcess International
September 21-25
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter